Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver June 22-26 2022     Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)   Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study - (06/26/22)   Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)   Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)   Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial - (06/26/22)   Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)   Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)   Voxilaprevir/Velpatasvir/Sofosbuvir Efficacy in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - Mark Mascolini (06/25/22)   Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) - (06/25/22)   Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)   Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)   Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)   Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide -Results of a "real world study" - (06/25/22)   No Detectable Resistance to Bulevirtide in Participants With Chronic Hepatitis D Through 24 Weeks of Treatment - (06/25/22)   Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy - (06/24/22)   Impact of Direct-Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers - (06/24/22)   Fibroscan-AST (FAST) score predicts liver-related outcomes in 1683 HIV-infected patients at risk for NAFLD - (06/24/22)   Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)   Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta - Mark Mascolini (06/24/22)   Don't Delay Rescue 2nd Line HCV Therapy "Dismal Prognosis" After First DAA Failure in People With Pretreatment Cirrhosis - Mark Mascolini (06/24/22)   Don't Delay DAAs in People Taking Antiepileptics, Elite Experts Advise - Mark Mascolini (06/24/22)   Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals - (06/24/22)   Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures - (06/24/22)   Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (06/24/22)   Polypharmacy and prevalence of multiple drug-drug interactions in hepatitis C patients treated with pangenotypic direct-acting antivirals: an analysis from three European countries - (06/24/22)   Use of comedication in patients with hepatitis C and addiction or drug abusetreated with direct-acting antivirals: implication in drug-drug interactions - (06/24/22)   Evaluation of Global Progress towards HBV and HCV elimination - off track - (06/23/22)   Healthcare Resource Utilization in Treatment-Naïve Patients With Compensated Cirrhosis Receiving 8-Weeks' Glecaprevir/Pibrentasvir Stratified by Drug Use and Socioeconomic Status: A Retrospective Chart Review - (06/23/22)   Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study - (06/23/22)   Reported Safety of HCV Direct-Acting Antivirals With Opioids: 2017 to 2021 - (06/23/22)   Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study - High Cure Rates - (06/23/22)   Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry - (06/23/22)   Treating HCV in Dual Diagnosis Acute Psychiatric Inpatients with Substance Use Disorder - (06/23/22)   Efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection: a systematic review and meta-analysis - (06/23/22)   Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with Hepatitis C: Data from the ASCEND and ANCHOR investigations - (06/23/22)   Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset - in order to achieve HCV Elimination with Focused Treatment Approaches - (06/23/22)   Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: Multicenter, single arm, phase 2 Study The HepNet acute HCV V study - (06/23/22)   Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial - (06/23/22)   Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure - (06/23/22)   Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients - (06/23/22)   Establishing a Protocol for Management and DAA Treatment of HCV During Pregnancy: adherence to a co-located care protocol - (06/23/22)   National HCV Paediatric Multidisciplinary Operational Delivery Network (pMDT ODN) - (06/23/22)   From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (06/23/22)   REAL-WORLD VALUE AND INNOVATION OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C AT Kaiser PERMANENTE SOUTHERN CALIFORNIA - (06/23/22)